EXCLUSIVE: Rep. Mike Haridopolos says TrumpRx is “huge play” to cut drug costs: “he actually did it”

Rep. Mike Haridopolos (R., Fla.) is praising President Trump’s TrumpRx initiative as a major step toward lowering prescription drug prices, telling the Washington Reporter the program is delivering on a long-promised goal in Washington.

“It’s a huge play, everyone talked about reducing prescription drug costs, and he actually did it,” Haridopolos said. “It’s about time we stop subsidizing the rest of the world. I’m so pleased by this direction, and it’s one of the ways that we can bring down costs for everyday Americans.”

Haridopolos’ comments add to a growing number of Republicans highlighting TrumpRx as a key affordability win. As the Reporter previously reported, Sen. Eric Schmitt (R., Mo.) pointed to the program’s ability to give patients direct access to lower-cost medications, calling the portal “important” for constituents facing high prices. 

The TrumpRx platform has been promoted as a way to reduce prescription costs by allowing Americans to purchase drugs at significantly discounted rates, in some cases by as much as 80 percent by bypassing middlemen and insurers. 

Haridopolos’ focus on pricing reflects a broader Republican argument that TrumpRx and negotiations with manufacturers can deliver affordability wins in an area that Democrats have failed to deliver. That message has increasingly resonated with members looking for clear, defensible healthcare wins ahead of the midterms.

The Reporter has also documented additional GOP support for the initiative in its ongoing coverage of TrumpRx, including lawmaker comments emphasizing the program’s direct-to-consumer model and its impact on out-of-pocket costs.

With more members now publicly backing the effort, TrumpRx is emerging as a central part of the Republican case that they are delivering tangible cost relief on healthcare.